One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes.
One-year experience of hybrid closed-loop system in children and adolescents with type 1 diabetes previously treated with multiple daily injections: drivers to successful outcomes.
复制标题
混合闭环系统在既往接受每日多次注射治疗的1型糖尿病儿童和青少年中的一年经验：成功结局的驱动因素
DOI：
10.1007/s00592-020-01607-4
复制
发表时间：
2021-03
影响因子：
3.8
通讯作者：
Hussain K
中科院分区：
文献类型：
--
作者：
Petrovski G;Al Khalaf F;Campbell J;Umer F;Almajaly D;Hamdan M;Hussain K
评价1年混合闭环（HCL）系统对既往接受每日多次注射（MDI）治疗的1型糖尿病（T1 D）儿童和青少年血糖控制的影响。 这是一项为期1年的观察性研究，是之前在卡塔尔Sidra Medicine进行的T1 D儿科患者3个月前瞻性研究的延续。该研究招募了年龄在7-18岁之间、T1 D> 1年、使用MDI进行自我血糖监测或连续血糖监测、既往无胰岛素泵使用经验、HbA 1c水平< 12.5%（< 113 mmol/mol）的个体。在使用HCL的前3个月后，在6、9和12个月时对患者进行随访，获得HbA 1c并收集泵数据。启动HCL的所有30名参与者（年龄10.24 ± 2.6岁）在自动模式下完成了12个月的HCL系统使用。在HCL系统使用的12个月期间，参与者使用探头的时间为88.4 ± 6.5%，自动模式使用率为85.6 ± 7.4%。HbA 1c从基线时的8.2 ± 1.4%（66 ± 15.3 mmol/mol）降至3个月时的6.7 ± 0.5%（50 ± 5.5 mmol/mol）（p = 0.02），并在12个月时保持稳定，降至7.1 ± 0.6（54 ± 6.6 mmol/mol）（p = 0.02）。TIR（70-180 mg/dL）从基线时的46.9%增加至1个月时的71.9%，并在使用HCL的12个月期间保持在70%以上。HCL系统（MiniMed 670 G）在既往接受MDI治疗的儿童和青少年中可在第一个月内立即显著改善血糖结局（HbA 1c和范围内时间）。在自动模式启动后的1年内，血糖控制得到了改善。
To evaluate the effect of a 1-year hybrid closed-loop (HCL) system on glycemic control in children and adolescents with type 1 diabetes (T1D) previously treated with multiple daily injections (MDI). This was a 1-year observational study, as a continuation of the previous 3 months prospective study of pediatric patients with T1D conducted at Sidra Medicine in Qatar. The study enrolled individuals aged 7–18 years with T1D > 1 year, on MDI with self-monitoring of blood glucose or continuous glucose monitoring, with no prior pump experience, and with an HbA1c level < 12.5% (< 113 mmol/mol). After the first 3 months of HCL use, patients were followed at 6, 9 and 12 months, where HbA1c was obtained and pump data were collected. All 30 participants (age 10.24 ± 2.6 years) who initiated HCL completed 12 months of HCL system use in Auto Mode. The participants used the sensor 88.4 ± 6.5% of the time with Auto Mode usage 85.6 ± 7.4% during 12 months of HCL system use. HbA1c decreased from 8.2 ± 1.4% (66 ± 15.3 mmol/mol) at baseline, to 6.7 ± 0.5% (50 ± 5.5 mmol/mol) at 3 months (p = 0.02) and remained stable to 7.1 ± 0.6 (54 ± 6.6 mmol/mol) at 12 months (p = 0.02). TIR (70–180 mg/dL) increased from 46.9% at baseline to 71.9% at 1 month and remained above 70% during the 12 months of HCL use. HCL system (MiniMed 670G) in children and adolescents previously treated with MDI significantly improves glycemic outcomes (HbA1c and Time in Ranges) immediately during the first month. This improved glycemic control was maintained over the 1 year following Auto Mode initiation.
登录
查看更多内容
影响因子：
16.2
作者：
Danne T;Nimri R;Battelino T;Bergenstal RM;Close KL;DeVries JH;Garg S;Heinemann L;Hirsch I;Amiel SA;Beck R;Bosi E;Buckingham B;Cobelli C;Dassau E;Doyle FJ 3rd;Heller S;Hovorka R;Jia W;Jones T;Kordonouri O;Kovatchev B;Kowalski A;Laffel L;Maahs D;Murphy HR;Nørgaard K;Parkin CG;Renard E;Saboo B;Scharf M;Tamborlane WV;Weinzimer SA;Phillip M
通讯作者：
Phillip M
影响因子：
3.4
作者：
DiMeglio, Linda A.;Acerini, Carlo L.;Maahs, David M.
通讯作者：
Maahs, David M.
影响因子：
3.4
作者：
Messer, Laurel H.;Berget, Cari;Forlenza, Gregory P.
通讯作者：
Forlenza, Gregory P.
影响因子：
5.4
作者：
Garg SK;Weinzimer SA;Tamborlane WV;Buckingham BA;Bode BW;Bailey TS;Brazg RL;Ilany J;Slover RH;Anderson SM;Bergenstal RM;Grosman B;Roy A;Cordero TL;Shin J;Lee SW;Kaufman FR
通讯作者：
Kaufman FR
影响因子：
16.2
作者：
Lal, Rayhan A.;Basina, Marina;Wilson, Darrell M.
通讯作者：
Wilson, Darrell M.